Palliative Care in Chronic Obstructive Pulmonary Disease: A Comprehensive Clinical Review

 Palliative Care in Chronic Obstructive Pulmonary Disease: A Comprehensive Clinical Review

Authors: Dr. Shekhar Ingle and Team, Doctor's Forum for All 🏥

Review by Dr. Gunjan chanchalani ma'am.

Copyright: © 2026 Dr. Shekhar Ingle and Team, Doctor's Forum for All. All rights reserved.

Disclaimer: This article is for educational and clinical reference purposes only. It does not replace individualized clinical judgment, local protocols, or specialist consultation. Medication doses should be verified with current formularies and adjusted to patient-specific factors.

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. It's a life-limiting condition. People with COPD endure chronic dyspnoea, cough, fatigue, anxiety, depression, and a quality of life that erodes slowly. Palliative care remains underused in this population. That's a problem.

Objective: This review provides a clinically verified framework for integrating palliative care into COPD management. It covers symptom assessment, pharmacological and non-pharmacological interventions, advance care planning, models of care delivery, and end-of-life management.

Methods: A structured narrative review was conducted using peer-reviewed guidelines, systematic reviews, randomized controlled trials, and consensus statements published between 2000 and 2026. Key sources included the European Respiratory Society, Spanish Society of Pulmonology and Thoracic Surgery (SEPAR), Spanish Society of Palliative Care (SECPAL), BMJ Best Practice, and Cochrane systematic reviews.

Results: Palliative care in COPD requires a needs-based approach rather than one based on prognosis alone. Symptom management includes opioids for refractory dyspnoea, though evidence is mixed, along with fan therapy, pulmonary rehabilitation, and psychosocial support. Advance care planning is crucial but underutilised. Multiple models of proactive palliative care exist, including multidisciplinary integrated services, nurse-led care, home-based care, and telehealth. End-of-life care should prioritise comfort and dignity.

Conclusion: Palliative care belongs in COPD management from diagnosis, not just at the end. It should run alongside disease-directed therapy. The evidence supports early integration, but implementation remains patchy. Clinicians need to get better at this.

Keywords: COPD, palliative care, dyspnoea, advance care planning, end-of-life care, integrated care, symptom management.

1. Introduction

Here's the thing about COPD. It kills slowly. It kills relentlessly. And for too long, we've treated it as a disease of the lungs alone. That's a mistake.

COPD is the third leading cause of death globally. The numbers are staggering. But numbers don't capture what it's like to gasp for air while sitting still. They don't capture the anxiety that comes with every breath. The fatigue that makes getting dressed feel like running a marathon. The depression that settles in when you realise this isn't getting better.

People with COPD experience physical and psychological symptoms that wreck their quality of life. Their caregivers face their own toll—personal, social, financial. It's a mess. A predictable mess, but a mess nonetheless.

Recent emphasis has shifted toward early referral to palliative care services. Why? Because it enhances prognostic awareness, clarifies goals of care, and manages symptoms. That's the theory. In practice, palliative care in COPD is still seen as something you do when nothing else works. That needs to change.

The European Respiratory Society defines palliative care for COPD as a holistic, multidisciplinary, person-centred approach. It aims to control symptoms and improve quality of life. That's not end-of-life care. That's good care. Period.

2. Methods

This review was conducted using a structured search of PubMed, Cochrane Library, EMBASE, and clinical guideline databases. Search terms included "COPD," "palliative care," "dyspnoea," "advance care planning," "opioids," "pulmonary rehabilitation," "integrated care," and "end-of-life care."

Inclusion criteria: systematic reviews, randomized controlled trials, clinical practice guidelines, consensus statements, and large observational studies published in English between 2000 and 2026. Key guidelines consulted included the SEPAR-SECPAL consensus document (2026), the BMJ Best Practice topic on COPD (updated May 2025), and several 2025 narrative reviews and meta-analyses on palliative care models and symptom management.

3. Results

3.1 The Case for Early Palliative Care

A 2026 consensus document from SEPAR and SECPAL laid out 70 evidence-based recommendations. The key message? Use a needs-based approach. Don't wait for a prognosis. Identify patients with palliative care needs early. Integrate palliative care alongside disease-directed therapies. Adoption of these recommendations is expected to improve quality of life and reduce symptom burden.

A 2025 narrative review identified five key models of proactive palliative care for COPD: multidisciplinary integrated services, nurse-led care, hospice and residential aged care, home-based care, and telemonitoring/telehealth. Each model shares common elements. Normalisation of palliative principles within routine care. Diverse delivery settings. Flexibility.

The problem? Implementation. A scoping review on integrating rehabilitation and palliation found that while guidelines increasingly support integrated care models, practical implementation remains limited and poorly defined. Barriers include lack of conceptual clarity, limited evidence of effect, and unclear caregiver roles.

3.2 Symptom Assessment and Management

3.2.1 Dyspnoea

Dyspnoea is the hallmark. It's what patients fear most. And managing it is complicated.

Opioids. The evidence is mixed. A 2025 meta-analysis published in Heliyon looked at ten studies, 380 patients. Morphine did not significantly reduce breathlessness. Standardized mean difference: −0.26. Confidence interval crossed zero. No impact on quality of life, oxygen saturation, or respiratory rate. Fatigue was the only side effect reaching statistical significance.

But here's the nuance. The BMJ Best Practice topic notes that one study suggested low doses of an opioid plus a benzodiazepine are safe and don't increase hospital admissions or mortality. Another found that regular, low-dose, oral sustained-release morphine for four weeks improved disease-specific health status in COPD patients with refractory breathlessness.

A 2025 critical review by Vozoris argued that opioids should not be used for dyspnoea management in COPD, citing respiratory harms. The debate is live. Clinicians need to weigh benefits against risks on a case-by-case basis.

Non-pharmacological interventions. Fans. Neuromuscular electrical stimulation. Chest wall vibration. These can relieve dyspnoea. Acupuncture and acupressure may also help. A Cochrane review concluded there's no evidence for or against benzodiazepines for breathlessness in advanced COPD.

3.2.2 Cough and Fatigue

Cough is persistent. It's exhausting. Management focuses on treating reversible causes—infection, reflux, postnasal drip. Opioids can suppress the cough reflex. Corticosteroids may reduce airway inflammation.

Fatigue is pervasive. It's not just tiredness. It's a bone-deep exhaustion that makes everything harder. Treat reversible causes: anaemia, hypothyroidism, depression. Exercise helps. So does energy conservation. Dexamethasone may provide short-term benefit in advanced disease.

3.2.3 Anxiety and Depression

These aren't optional extras. They're central. Anxiety and depression affect a huge proportion of COPD patients. They worsen outcomes. They make everything worse.

Screen for them. Use PHQ-9 or HADS. SSRIs are first-line pharmacotherapy. Cognitive behavioural therapy works. Mindfulness helps. Pulmonary rehabilitation programmes that integrate palliative care education show promise. A 2025 feasibility study found that integrating an education session about palliative care in pulmonary rehabilitation was meaningful for patients and had no undesirable effects.

3.3 Advance Care Planning

Advance care planning in COPD is a mess. A 2025 concept analysis identified four antecedents: COPD progression, decline in quality of life, attitude toward facing death, and interdisciplinary team approach. Four attributes: discussion process, documentation, support for facing death, holistic approach. Four consequences: dialogical process, improved decision-making support, physical impacts, psychological impacts.

The problem? Patients rarely discuss end-of-life issues. They have little access to palliative care. A 2025 study on doctor-facilitated denial found that many severe COPD patients are unaware of their treatment options and lack motivation for advance care planning. Denial, self-perceived health, and trust didn't significantly affect motivation.

The EU PAL-COPD project is trying to fix this. It's the first large-scale international trial integrating palliative care into respiratory care for COPD. The intervention focuses on identification, advance care planning, and ongoing review of palliative care needs, starting when the patient is hospitalised for an exacerbation.

3.4 Pulmonary Rehabilitation and Palliative Care

These aren't opposites. They're complementary. A 2025 scoping review on integrating rehabilitation and palliation found six overarching themes: overlapping treatment goals, timing of services, inclusion of advance care planning, attention to existential and spiritual dimensions, barriers to integration, and the role of informal caregivers.

The overlap is obvious. Both aim to improve function and quality of life. Both address symptoms. Both support patients and families. Integrating them makes sense. Several studies highlight the opportunity to incorporate end-of-life discussions into traditional rehabilitation programmes. Introducing palliative care principles earlier in rehabilitation may increase the number of patients receiving appropriate end-of-life care.

3.5 End-of-Life Care

Recognising the terminal phase in COPD is hard. The trajectory is unpredictable. Death can come suddenly from an exacerbation, or slowly from progressive respiratory failure.

Features suggesting imminent death include progressive decline despite maximal therapy, refractory dyspnoea at rest, worsening cachexia, delirium, and the patient expressing a desire for comfort-focused care.

Symptom control in the last days of life requires careful medication management. Morphine subcutaneously for dyspnoea. Midazolam for agitation and anxiety. Glycopyrronium for respiratory secretions. Haloperidol for nausea. Stop non-essential medications. Avoid intravenous fluids unless for comfort.

BMJ Best Practice recommends that end-of-life care and hospice admission should be considered for patients with very advanced disease. Discussions should be held early in the course of the disease, before acute respiratory failure develops.

4. Discussion

4.1 Why Palliative Care Gets Ignored in COPD

Let's be honest. Palliative care in COPD is underused. Why?

First, the disease trajectory is unpredictable. Unlike cancer, where there's often a clear terminal phase, COPD can kill you suddenly or drag on for years. Clinicians struggle to know when to refer.

Second, there's a misconception that palliative care equals hospice. It doesn't. Palliative care is about symptom management and quality of life, alongside disease-directed therapy. It can start at diagnosis.

Third, there's a lack of trained palliative care clinicians in respiratory settings. And there's a lack of respiratory clinicians trained in palliative care.

Fourth, patients often don't want to talk about it. Doctor-facilitated denial is real. Many severe COPD patients are unaware of their treatment options and lack motivation for advance care planning.

4.2 The Opioid Debate

The evidence on opioids for dyspnoea in COPD is genuinely mixed. The 2025 meta-analysis found no significant benefit. But other studies suggest low-dose opioids can help. A critical review argued against their use entirely.

What's a clinician to do?

Individualise. Consider the patient's goals, the severity of dyspnoea, the risk of respiratory depression, and the availability of non-pharmacological alternatives. Start low if you're going to use them. Monitor closely. Have a plan for titration and de-escalation.

The debate isn't going away. More research is needed. But in the meantime, clinicians need to make decisions. And those decisions should be grounded in the patient's values and preferences, not just the latest meta-analysis.

4.3 Models of Care

The 2025 narrative review identified five models of proactive palliative care for COPD: multidisciplinary integrated services, nurse-led care, hospice and residential aged care, home-based care, and telemonitoring/telehealth.

Which is best? There's no single answer. The best model depends on local resources, patient preferences, and the healthcare system.

Multidisciplinary integrated services bring together respiratory and palliative care teams. Nurse-led care can provide continuity and expertise. Home-based care allows patients to stay where they want to be. Telehealth can extend reach, especially for patients in rural areas.

The key is flexibility. Successful palliative care models must be practical, accessible, and innovative. They must respond to individuals' complex and evolving needs. They must foster multidisciplinary collaboration. And they must optimally utilise local healthcare resources.

4.4 The EU PAL-COPD Trial

This is a big deal. EU PAL-COPD is the first large-scale international trial integrating palliative care into respiratory care for COPD. It's evaluating an intervention called ICLEAR-EU. The intervention focuses on identification, advance care planning, and ongoing review of palliative care needs. It starts when the patient is hospitalised for an exacerbation.

Why is this important? Because hospitalisations for exacerbations are a critical moment. Patients are sick. They're scared. They're thinking about their mortality, even if they don't say it. It's the perfect time to start conversations about goals of care and advance care planning.

The trial aims to improve patient and family well-being. It also aims to set a new standard for coordinated care in respiratory and palliative services across Europe.

4.5 Gaps in Evidence

Despite advances, gaps remain. We need better evidence on opioid use for dyspnoea in COPD. We need to understand which models of care work best and for whom. We need to develop and test interventions that integrate palliative care into routine COPD management. We need to train clinicians. We need to overcome the cultural and systemic barriers that keep palliative care separate from respiratory care.

The EU PAL-COPD trial is a step in the right direction. But it's just one trial. We need more.

5. Conclusion

Palliative care in COPD is not optional. It's essential. The evidence supports early integration. The guidelines recommend it. The patients need it.

But implementation lags. Clinicians are unsure when to refer. Patients are reluctant to engage. Systems aren't designed for integrated care.

The solution requires effort at every level. Education. Training. Policy changes. Better research. And a cultural shift that recognises palliative care as part of good respiratory care, not something separate.

Start early. Use a needs-based approach. Address symptoms. Support families. Plan for the end. It's not complicated in principle. It's just hard in practice.

References

1. D'Andria Ursoleo J, Bottussi A, Sullivan DR, et al. Chronic obstructive pulmonary disease: A narrative synthesis of its hallmarks for palliative care clinicians. Eur J Intern Med. 2025;133:25-34. doi:10.1016/j.ejim.2024.12.033

2. Minami K, et al. Advance care planning for patient with chronic obstructive pulmonary disease: An evolutionary concept analysis. Jpn J Nurs Sci. 2025;22(1):e12633. doi:10.1111/jjns.12633

3. Pascoe A, et al. A narrative review of proactive palliative care models for people with COPD. Ther Adv Respir Dis. 2025;19:17534666241310987. doi:10.1177/17534666241310987

4. Meta-analysis on the effectiveness and safety of morphine in managing clinical symptoms of chronic obstructive pulmonary disease. Heliyon. 2025;11(10):e43365. doi:10.1016/j.heliyon.2025.e43365

5. BMJ Best Practice. Chronic obstructive pulmonary disease (COPD) – Management. Updated May 13, 2025. https://bestpractice.bmj.com/topics/en-us/7[reference:31]

6. Marsaa K, et al. Integration of rehabilitation and palliation for people with severe lung disease or heart failure - a scoping review. Eur Clin Respir J. 2025;12(1):2529052. doi:10.1080/20018525.2025.2529052

7. De Miguel-Díez J, Salcedo-Perís T, Figueira Gonçalves JM, Golpe R. Consensus Document on the Multidisciplinary Management of Advanced-Stage Respiratory Diseases. Arch Bronconeumol. 2026;62(7). (SEPAR-SECPAL consensus)

8. EU PAL-COPD: Integrating palliative care in treatment for advanced COPD across Europe. ERS Conference Abstract. 2025. https://publications.ersnet.org

9. Vozoris NT. Recent discoveries from clinical trials: why opioids should not be used for dyspnea management in COPD. Expert Rev Respir Med. 2025. https://www.semanticscholar.org

10. Palliative care education as an integrated component of pulmonary rehabilitation: A real-world mixed-methods feasibility study. Respir Med. 2025;241:108034. doi:10.1016/j.rmed.2025.108034

Prepared By: Dr. Shekhar Ingle and Team, Doctor's Forum for All 🏥

Copyright: © 2026 Dr. Shekhar Ingle and Team, Doctor's Forum for All. All rights reserved.

Date: 2026